Back to top

GSK’s New Phase 3 Asthma Trial Sets the Stage for the Next Wave in Respiratory Growth

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The PERSIST ASTHMA-1 study, officially titled a Phase 3 randomized tria...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

GSK PLC Sponsored ADR (GSK)